

U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Lawrence & Memorial Hospital</p> <p>2. 365 Montauk Avenue New London, Connecticut 06320-4769</p>	<p>In accordance with the letter dated July 1, 2013,</p> <p>3. License number 06-09261-01 is amended in its entirety to read as follows:</p> <hr/> <p>4. Expiration date February 28, 2014</p> <hr/> <p>5. Docket No. 030-01275 Reference No. 06-30826-01</p>
--	---

<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Any byproduct material permitted by 10 CFR 35.500</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p> <p>D. Sealed Sources (Isotope Products Models A-3410 and NES-8426, and AEA Technology Model GDLIN2)</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p> <p>C. 300 millicuries</p> <p>D. 120 millicuries per source and 300 millicuries total</p>
--	---	--

9. Authorized use:
- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
 - B. Any imaging and localization study permitted by 10 CFR 35.200.
 - C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300, for which the patient can be released under the provisions of 10 CFR 35.75.
 - D. Diagnostic medical use of sealed sources permitted by 10 CFR 35.500 in compatible devices registered pursuant to 10 CFR 30.32(g).

CONDITIONS

- 10. A. Licensed material may be used or stored only at the licensee's facilities located at 365 Montauk Avenue, New London, Connecticut.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
06-09261-01

Docket or Reference Number
030-01275
06-30826-01

Amendment No. 88

- B. Licensed material in Item 6.B. may be used or stored only at the licensee's facilities located at 196 Parkway South, Suite 102 and 103, Waterford, Connecticut.
11. The Radiation Safety Officer for this license is John Sorrentino, M.D.
12. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for medical use as indicated:

<u>Authorized Users</u>	<u>Material and Use</u>
Charles W. Andrias, M.D.	35.200; 35.500
Thomas J. Manning, M.D.	35.100; 35.200; 35.300 except Iodine-131 in quantities greater than 33 millicuries; 35.500
John Sutphen, M.D.	35.100; 35.200; 35.500
Leonard A. Copertino, M.D.	35.100; 35.200; 35.500
Sheldon Robbins, M.D.	35.100; 35.200; oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries; 35.500
Francis J. Mirecki, M.D.	35.200; 35.500
John Sorrentino, M.D.	35.100; 35.200; oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries
Ira Sitko, M.D.	35.100; 35.200; 35.500
Patrick Lahr, M.D.	35.100; 35.200; 35.300 except Iodine-131 in quantities greater than 33 millicuries
Todd Blue, M.D.	35.100; 35.200; 35.500
Valerie Popkin, M.D.	35.200; 35.500
Preston R. Lamberton, M.D.	35.300

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
06-09261-01

Docket or Reference Number
030-01275
06-30826-01

Amendment No. 88

Authorized Users

Material and Use

Mark J. Somers, M.D.

35.200; 35.500

Jon Gaudio, M.D.

35.200; 35.500


Arun Basu, M.D.

35.100; 35.200; Oral administration of sodium in quantities less than or equal to 33 millicuries

Yasmine Khan, M.D.

Oral administration of sodium iodide I-131

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
06-09261-01

Docket or Reference Number
030-01275
06-30826-01

Amendment No. 88

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- | | | |
|----|------------------------------------|---------------|
| A. | Application dated January 14, 2004 | [ML040340356] |
| B. | Letter dated May 20, 2004 | [ML041410419] |
| C. | Letter dated February 25, 2008 | [ML080930133] |
| D. | Letter dated September 9, 2008 | [ML082620675] |
| E. | Letter dated September 24, 2008 | [ML082740553] |
| F. | Letter dated December 15, 2008 | [ML083510564] |
| G. | Letter dated February 13, 2009 | [ML090710252] |
| H. | Facsimile dated April 3, 2009 | [ML090960526] |
| I. | Letter dated August 3, 2011 | [ML112211228] |
| J. | Letter dated November 18, 2011 | [ML113290231] |
| K. | Letter dated February 6, 2012 | [ML120390401] |
| L. | Letter dated February 22, 2012 | [ML120540072] |
| M. | Letter dated April 10, 2012 | [ML12107A316] |
| N. | Letter dated April 9, 2013 | [ML13108A028] |
| O. | Letter dated July 1, 2013 | [ML13203A096] |

For the U.S. Nuclear Regulatory Commission

Date September 16, 2013

By *Original signed by Maryann Abogunde*
 Maryann Abogunde
 Medical Branch
 Division of Nuclear Materials Safety
 Region I
 King of Prussia, Pennsylvania 19406